Biodesix (BDSX)
NASDAQ:BDSX
BDSX Stock Chart & Stats
$15.15
-$0.03(-2.01%)
At close: 4:00 PM EST
$15.15
-$0.03(-2.01%)
Day’s Range― - ―
52-Week Range$3.42 - $20.21
Previous CloseN/A
Volume171.18K
Average Volume (3M)107.55K
Market Cap
$149.35M
Enterprise Value$168.27M
Total Cash (Recent Filing)$18.99M
Total Debt (Recent Filing)$72.85M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
May 13, 2026EPS Estimate
-1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding9,858,358
10 Day Avg. Volume48,205
30 Day Avg. Volume107,552
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-20.83
Price to Sales (P/S)0.58
P/FCF Ratio-2.18
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue1.90
Enterprise Value/Gross Profit2.34
Enterprise Value/Ebitda-7.66
Forecast
1Y Price Target
$30.00Price Target Upside98.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-3.16
Revenue Forecast (FY)$108.68M
Bulls Say, Bears Say
Bulls Say
Balance Sheet And ValuationA recent capital raise combined with an amended debt facility materially strengthened the balance sheet, reducing financing pressure and highlighting a valuation discount relative to peers as potential upside.
Commercial ExecutionExpansion and reconfiguration of the sales force, along with planned new hires, is poised to deepen market penetration and drive higher test volumes and reimbursement gains.
Profitability And MarginsPositive adjusted EBITDA driven by higher test volumes and stronger average revenue per test signals improving operating leverage and supports continued margin expansion.
Bears Say
Clinical Development TimelineA delayed clinical study readout caused by required patient follow-up could push back key data milestones and slow progress on clinical validation and commercialization plans.
Financing RiskOngoing reliance on periodic capital raises to fund operations indicates persistent financing risk and uncertainty around the company’s ability to achieve durable profitability without additional funding.
Revenue Sustainability And Margin PressureSeasonality in patient collections and the potential need for further commercial expansion could create revenue volatility and raise costs, putting pressure on margins and growth sustainability.
Biodesix News
BDSX FAQ
What was Biodesix’s price range in the past 12 months?
Biodesix lowest stock price was $3.42 and its highest was $20.21 in the past 12 months.
What is Biodesix’s market cap?
Biodesix’s market cap is $149.35M.
When is Biodesix’s upcoming earnings report date?
Biodesix’s upcoming earnings report date is May 13, 2026 which is in 48 days.
How were Biodesix’s earnings last quarter?
Biodesix released its earnings results on Feb 26, 2026. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.86 by $0.37.
Is Biodesix overvalued?
According to Wall Street analysts Biodesix’s price is currently Undervalued.
Does Biodesix pay dividends?
Biodesix does not currently pay dividends.
What is Biodesix’s EPS estimate?
Biodesix’s EPS estimate is -1.08.
How many shares outstanding does Biodesix have?
Biodesix has 9,858,358 shares outstanding.
What happened to Biodesix’s price movement after its last earnings report?
Biodesix reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.86. Following the earnings report the stock price went up 7.806%.
Which hedge fund is a major shareholder of Biodesix?
Currently, no hedge funds are holding shares in BDSX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biodesix Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.00 (98.02% Upside)
$30.00 (98.02% Upside)
Hedge Fund Trend
Decreased
By 15.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 11.5%
Last 30 Days ▲ 11.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-79.44%
12-Months-Change
Fundamentals
Return on Equity
-302.55%
Trailing 12-Months
Asset Growth
-24.26%
Trailing 12-Months
Company Description
Biodesix
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
BDSX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented multiple strong operational and commercial positives: accelerating revenue growth, industry‑leading gross margins, the company's first positive adjusted EBITDA quarter, expanding sales coverage and strategic development partnerships. These highlights outweigh near‑term headwinds — such as seasonality, a $1M one‑time collection that partially boosted Q4 results, delayed clinical readouts for ALTITUDE, ongoing full‑year losses, and continued investment‑driven expense growth — which management is addressing through operational leverage, cash raises and loan amendments. On balance the call communicates momentum toward scaled, profitable growth while acknowledging execution and timing risks in the near term.View all BDSX earnings summariesBDSX Stock 12 Month Forecast
Average Price Target
$30.00
▲(98.02% Upside)